ClinicalTrials.gg
TerminatedNCT03551522Updated Sep 15, 2022Results posted

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Seladelpar and Placebos in NASH - Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Terminated at 14 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-09-15.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Why this study was terminated
unexpected histological findings

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
8th of 16
181 · median 161
Started
2018
with 1 other
Phase 2
11 of 16
none open now
Registered
14th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 8th largest by enrollment, is one of 2 that started in 2018, is one of 11 in phase 2, and was the 14th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH)

OLE phase was not analyzed due to the early termination of the study

Read the detailed description

Primary Objectives

  1. To evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the DB phase
  2. To evaluate the safety and tolerability of seladelpar in the DB and OLE phases

Secondary Objectives

  1. To evaluate the effect of seladelpar on MRI- PDFF at Week 26 and Week 52 in the DB phase
  2. To evaluate the effect of seladelpar on histological improvement of nonalcoholic fatty liver disease activity score (NAS) at Week 52 in the DB phase
  3. To evaluate the effect of seladelpar on histological improvement of fibrosis at Week 52 in the DB phase
  4. To evaluate the effect of seladelpar on metabolic biochemical markers and biochemical markers of inflammation in the DB and OLE phases
03

Conditions studied

  • NASH - Nonalcoholic Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

DB Inclusion Criteria:

  1. Must be able to provide written (signed and dated) and any authorizations required by local law
  2. 18 to 75 years old (inclusive)
  3. Histological evidence of definite NASH on a liver (obtained during the screening period or historical liver biopsy obtained no more than 90 days prior to the initial screening visit)
  4. NAS of 4 points or greater with a score of at least 1 point in each component (steatosis, lobular inflammation, and ballooning)
  5. Fibrosis stage 1, 2, or 3 on liver biopsy
  6. MRI-PDFF ≥ 10%
  7. Females of must use at least one barrier and a second effective birth control method during the study and for at least 30 days after the last dose of study drug. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose of study drug.

DB Exclusion Criteria:

  1. Significant alcohol consumption, defined as more than 2 drink units per day (equivalent to 20 g) in women and 3 drink units per day (equivalent to 30 g) in men, or inability to reliably quantify alcohol intake
  2. Treatment with drugs associated with nonalcoholic fatty liver disease (NAFLD) (amiodarone, methotrexate, oral at doses greater than 5 mg/day, tamoxifen, estrogens at doses greater than those used for hormone replacement or contraception, anabolic steroids (such as testosterone and valproic acid) for more than 4 weeks within the last 2 months prior to the initial screening
  3. Treatment with pioglitazone or high-dose vitamin E (>400 IU/day) within the last 2 months prior to the initial screening
  4. Initiation of treatment with a glucagon-like peptide-1 (GLP-1) agonist or a dose change within the last 2 months prior to the initial screening
  5. Prior or planned bariatric surgery (a prior reversed sleeve gastrectomy is permitted)
  6. Poorly controlled type 2 diabetes mellitus as defined by [HbA1c] 9.5% or higher or type 1 diabetes mellitus
  7. Diabetic patients who are taking sodium/glucose cotransporter 2 (SGLT-2) inhibitors must be on a stable dose within 2 months prior to the initial screening and throughout the study
  8. Significant weight loss within the last 6 months (e.g., > 10%)
  9. Use of any weight-loss medication for 3 months prior to and during the study period
  10. (BMI) \< 18.5 kg/m2
  11. Hepatic decompensation defined as the presence of any of the following:

    • Serum albumin less than 3.5 g/dL
    • (INR) greater than 1.4 (unless due to therapeutic anticoagulants)
    • Total greater than 2 mg/dL with the exception of Gilbert syndrome
    • History of esophageal varices, ascites, or hepatic encephalopathy
  12. Other chronic liver diseases

    • Active as defined by presence of hepatitis B surface antigen (HBsAg)
    • Active as defined by presence of hepatitis C virus antibody (HCV AB) plus a positive HCV RNA
    • History or evidence of current active hepatitis
    • History or evidence of primary biliary cholangitis (PBC)
    • History or evidence of primary sclerosing cholangitis
    • History or evidence of Wilson's disease
    • History or evidence of alpha-1-antitrypsin deficiency
    • History or evidence of hemochromatosis
    • History or evidence of drug-induced liver disease, as defined exposure and history
    • Known bile duct obstruction
    • Suspected or proven liver cancer
  13. > 200 U/L
  14. AST \< 20 U/L
  15. Creatine kinase (CK) > (ULN)
  16. Serum creatinine > ULN
  17. \< lower limit of normal (LLN)
  18. Inability to obtain a liver biopsy
  19. History of biliary diversion
  20. Known history of (HIV) infection
  21. History of diagnosed or treated within 2 years

    • Recent localized treatment of squamous or non-invasive basal cell skin cancers is permitted
    • Cervical carcinoma in-situ is allowed if appropriately treated prior to Screening
    • Participants under active evaluation for malignancy are not eligible
  22. Active substance abuse, based on Investigator judgment, including inhaled or injected drugs, within 1 year prior to the initial screening
  23. Females who are pregnant or breastfeeding
  24. Patients unable to undergo MRI-PDFF due to:

    • to MRI examination
    • Severe claustrophobia impacting ability to perform MRI during the study, despite mild sedation/treatment with an anxiolytic
    • Weight or girth exceeds the scanner capacities
  25. Treatment with any other therapy or device within 30 days or within five half-lives, whichever is longer, prior to the initial screening
  26. Active, serious medical disease with likely \< 5 years
  27. Any other condition(s) that would compromise the safety of the subject or compromise study quality as judged by the Investigator

OLE Phase Enrollment Criteria

Subjects must fulfill the following before allowing to start OLE dosing:

  1. Provide informed consent on or before Day 1 and prior to any OLE-related study procedures.
  2. Completed through the Week 52 biopsy and Week 56 lab assessments in the DB phase
  3. Meet the above DB phase Inclusion and Exclusion Criteria before Day 1 of the OLE phase, with the exception of the following:

    • AST \< 20 U/L
    • Inability to obtain a liver biopsy (no new biopsy required for OLE)
    • Unable to undergo MRI-PDFF (no imaging performed in OLE)
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Seladelpar 10 mg

    Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.

    Drug: Seladelpar

  • Experimental
    Seladelpar 20 mg

    Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.

    Drug: Seladelpar

  • Experimental
    Seladelpar 50 mg

    Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.

    Drug: Seladelpar

  • Placebo comparator
    Placebo

    Subjects enrolled will receive seladelpar 10 mg, 20 mg, 50 mg or placebo daily for 52 weeks.

    Drug: Placebos

Interventions

  • 10 mg, 20 mg, or 50 mg

    Also known as: MBX-8025

  • DrugPlacebos

    Matching placebo Capsule

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)

    Evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the double-blind (DB) phase. MRI-PDFF Relative (Percent) Change From Baseline to Week 12 - ANCOVA - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS)

    Histopathology nonalcoholic fatty liver disease activity score (NAS) change from baseline ≤-2 (Improvements of 2 points or more in NAS) - mITT Population Total NAS score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8. Diagnosis of NASH (or, alternatively, fatty liver not diagnostic of NASH) should be made first, then NAS is used to grade activity. NAS scores of 0-2 occurred in cases largely considered not diagnostic of NASH, scores of 3-4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH. Scores of 5-8 occurred in cases that were largely considered diagnostic of NASH

    Time frame: Week 52

  2. Percent Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 and Week 52

    Alanine Aminotransferase (ALT) Relative (percent) change of from Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of alanine aminotransferase (ALT) is a marker of liver function improvement.

    Time frame: Week 12, Week 52

  3. Percent Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 and Week 52

    Relative (Percent) Change of Aspartate Aminotransferase (AST) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Aspartate Aminotransferase (AST) is a marker of liver function improvement.

    Time frame: Weeks 12, Week 52

  4. Percent Change From Baseline in Gamma Glutamyl Transferase (GGT) at Week 12 and Week 52

    Relative (Percent) Change of Gamma Glutamyl Transferase (GGT) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Gamma Glutamyl Transferase (GGT) is a marker of liver function improvement.

    Time frame: Weeks 12, Week 52

  5. Number of Participants With Decrease in MRI-PDFF ≥ 30% From Baseline at Week 12 and Week 52

    Number of Participants with a relative decrease in MRI-PDFF ≥30% (ie, percent change ≥ 30%) at Weeks 12, and 52/ET (Early Termination) in the DB phase - mITT Population. MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration. MRI-PDFF response defined as ≥30% relative decline in MRI-PDFF is associated with ≥1 stage improvement in fibrosis and may be used as a surrogate marker of fibrosis regression in early phase clinical trials for NASH

    Time frame: Week 12, Week 52

  6. Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52

    Percentage Change from Baseline in MRI-PDFF to Weeks 52//ET - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.

    Time frame: Week 52

  7. Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52

    Liver Biopsy Responders with reversal of NASH (ballooning score of 0 and lobular inflammation score of 0 or 1 and no worsening of hepatic fibrosis) at Week 52/ET. The reversal of NASH was defined as the absence of hepatocellular ballooning (score of 0) and no or minimal inflammation (lobular inflammation score of 0 or 1).

    Time frame: Week 52

  8. Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52

    Proportion of subjects with improvement by at least 1 stage in fibrosis without worsening of NASH (ie, improvement by at least 1 fibrosis stage without worsening of NAS) at Week 52/ET - Cochran-Mantel-Haenszel - mITTb Population There five liver fibrosis stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2: scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring)

    Time frame: Week 52

07

Results

Posted Jul 5, 2022

Participant flow

DB Phase
Participant flow — DB Phase
MilestonePeriod 1: Seladelpar 10 mgPeriod 1: Seladelpar 20 mgPeriod 1: Seladelpar 50 mgPeriod 1: PlaceboPeriod 2: Seladelpar 50 mg
Started535150270
Completed273432170
Not completed261718100
OLE Phase
Participant flow — OLE Phase
MilestonePeriod 1: Seladelpar 10 mgPeriod 1: Seladelpar 20 mgPeriod 1: Seladelpar 50 mgPeriod 1: PlaceboPeriod 2: Seladelpar 50 mg
Started000012
Completed00000
Not completed000012

Outcome measures

PrimaryPercentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)

Evaluate the effect of seladelpar on hepatic fat fraction, as assessed by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) at Week 12 in the double-blind (DB) phase. MRI-PDFF Relative (Percent) Change From Baseline to Week 12 - ANCOVA - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.

Time frame:
Week 12
Reported as:
Least squares mean · percentage of change from Baseline
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)
percentage of change from BaselineSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF)-9.76 ± 4.153-14.24 ± 4.329-13.00 ± 4.305-20.78 ± 5.555
Statistical analysis
  • Seladelpar 10 mg vs Placebo · ANCOVA · p = 0.0874 · Ls mean of difference: 11.02 · 95% CI -1.63 to 23.67
  • Seladelpar 20 mg vs Placebo · ANCOVA · p = 0.3151 · Ls mean of difference: 6.54 · 95% CI -6.28 to 19.37
  • Seladelpar 50 mg vs Placebo · ANCOVA · p = 0.2313 · Ls mean of difference: 7.78 · 95% CI -5.01 to 20.58
SecondaryPercentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS)

Histopathology nonalcoholic fatty liver disease activity score (NAS) change from baseline ≤-2 (Improvements of 2 points or more in NAS) - mITT Population Total NAS score represents the sum of scores for steatosis, lobular inflammation, and ballooning, and ranges from 0-8. Diagnosis of NASH (or, alternatively, fatty liver not diagnostic of NASH) should be made first, then NAS is used to grade activity. NAS scores of 0-2 occurred in cases largely considered not diagnostic of NASH, scores of 3-4 were evenly divided among those considered not diagnostic, borderline, or positive for NASH. Scores of 5-8 occurred in cases that were largely considered diagnostic of NASH

Time frame:
Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS)
Percentage of ParticipantsSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Percentage of Participants With Improvement of 2 Points or More in the Nonalcoholic Fatty Liver Disease Activity Score (NAS)23.145.237.032.0
SecondaryPercent Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 and Week 52

Alanine Aminotransferase (ALT) Relative (percent) change of from Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of alanine aminotransferase (ALT) is a marker of liver function improvement.

Time frame:
Week 12, Week 52
Reported as:
Least squares mean · percentage of change from Baseline
Percent Change From Baseline in Alanine Aminotransferase (ALT) at Week 12 and Week 52
percentage of change from BaselineSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Week 12-24.05 ± 4.154-32.92 ± 4.075-38.29 ± 3.907-9.57 ± 5.034
Week 52-28.60 ± 5.044-43.93 ± 4.844-40.60 ± 4.682-2.26 ± 6.252
SecondaryPercent Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 and Week 52

Relative (Percent) Change of Aspartate Aminotransferase (AST) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Aspartate Aminotransferase (AST) is a marker of liver function improvement.

Time frame:
Weeks 12, Week 52
Reported as:
Least squares mean · percentage of change from baseline
Percent Change From Baseline in Aspartate Aminotransferase (AST) at Week 12 and Week 52
percentage of change from baselineSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Week 12-14.02 ± 4.793-16.03 ± 4.686-17.88 ± 4.491-14.75 ± 5.834
Week 52-20.62 ± 5.988-26.43 ± 5.698-18.43 ± 5.536-4.54 ± 7.490
SecondaryPercent Change From Baseline in Gamma Glutamyl Transferase (GGT) at Week 12 and Week 52

Relative (Percent) Change of Gamma Glutamyl Transferase (GGT) From Baseline to Weeks 12 and Week 52 - mITT Population A decreased serum levels of Gamma Glutamyl Transferase (GGT) is a marker of liver function improvement.

Time frame:
Weeks 12, Week 52
Reported as:
Least squares mean · Percentage of change from Baseline
Percent Change From Baseline in Gamma Glutamyl Transferase (GGT) at Week 12 and Week 52
Percentage of change from BaselineSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Week 12-28.67 ± 3.848-37.78 ± 3.760-42.50 ± 3.626-6.40 ± 4.630
Week 52-27.93 ± 5.674-45.84 ± 5.401-35.11 ± 5.2550.71 ± 7.093
SecondaryNumber of Participants With Decrease in MRI-PDFF ≥ 30% From Baseline at Week 12 and Week 52

Number of Participants with a relative decrease in MRI-PDFF ≥30% (ie, percent change ≥ 30%) at Weeks 12, and 52/ET (Early Termination) in the DB phase - mITT Population. MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration. MRI-PDFF response defined as ≥30% relative decline in MRI-PDFF is associated with ≥1 stage improvement in fibrosis and may be used as a surrogate marker of fibrosis regression in early phase clinical trials for NASH

Time frame:
Week 12, Week 52
Reported as:
Count of participants · Participants
Number of Participants With Decrease in MRI-PDFF ≥ 30% From Baseline at Week 12 and Week 52
ParticipantsSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Week 12121298
Week 52/ET81985
SecondaryPercentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52

Percentage Change from Baseline in MRI-PDFF to Weeks 52//ET - mITT Population MRI-PDFF exam was used to quantify the hepatic proton density fat fraction noninvasively. The fat fraction is the proportion of mobile protons in liver tissue attributable to fat and thus, is a noninvasive magnetic resonance-based biomarker of liver triglyceride concentration.

Time frame:
Week 52
Reported as:
Mean · percentage of change from Baseline
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52
percentage of change from BaselineSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Percentage Change From Baseline in Magnetic Resonance Imaging-proton Density Fat Fraction (MRI-PDFF) at Week 52-9.76 ± 27.323-23.98 ± 30.666-7.99 ± 30.650-18.30 ± 27.872
SecondaryNumber of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52

Liver Biopsy Responders with reversal of NASH (ballooning score of 0 and lobular inflammation score of 0 or 1 and no worsening of hepatic fibrosis) at Week 52/ET. The reversal of NASH was defined as the absence of hepatocellular ballooning (score of 0) and no or minimal inflammation (lobular inflammation score of 0 or 1).

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 52
ParticipantsSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Number of Liver Biopsy Responders With Reversal of NASH Reversal of NASH (Ballooning Score of 0 and Lobular Inflammation Score of 0 or 1) and no Worsening of Hepatic Fibrosis at Week 5248122
SecondaryPercentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52

Proportion of subjects with improvement by at least 1 stage in fibrosis without worsening of NASH (ie, improvement by at least 1 fibrosis stage without worsening of NAS) at Week 52/ET - Cochran-Mantel-Haenszel - mITTb Population There five liver fibrosis stages (F0: no scarring (no fibrosis); F1: minimal scarring; F2: scarring has occurred and extends outside the liver area (significant fibrosis); F3: fibrosis spreading and forming bridges with other fibrotic liver areas (severe fibrosis); F4: cirrhosis or advanced scarring)

Time frame:
Week 52
Reported as:
Count of participants · Participants
Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52
ParticipantsSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
Percentage of Participants With Improvement by at Least 1 Stage in Fibrosis From Baseline at Week 12 and Week 52910175

Adverse events

Collected over Through DB Phase (from first dose of DB phase study drug, and up to 30 days after last dose of DB phase study drug or 1 day before the first dose of OLE phase, whichever was earlier), up to 56 weeks. AEs are only summarized in DB phase, not OLE phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Seladelpar 10 mg0/53 (0%)1/53 (1.9%)45/53 (84.9%)
Seladelpar 20 mg0/51 (0%)3/51 (5.9%)49/51 (96.1%)
Seladelpar 50 mg0/50 (0%)5/50 (10%)48/50 (96%)
Placebo0/27 (0%)0/27 (0%)25/27 (92.6%)
Most frequent serious events
Most frequent serious events
EventSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
DiverticulitisInfections and infestations0/530/512/500/27
Faeces discolouredGastrointestinal disorders0/530/511/500/27
Non-cardiac chest painGeneral disorders0/531/511/500/27
Gastroenteritis Escherichia coliInfections and infestations0/530/511/500/27
Intentional overdoseInjury, poisoning and procedural complications0/530/511/500/27
Procedural painInjury, poisoning and procedural complications0/530/511/500/27
Obstructive pancreatitisGastrointestinal disorders0/531/510/500/27
DizzinessNervous system disorders0/531/510/500/27
PneumoniaInfections and infestations1/530/510/500/27
Post procedural complicationInjury, poisoning and procedural complications1/530/510/500/27
Most frequent other events
Showing 10 of 36
Most frequent other events
EventSeladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlacebo
HeadacheNervous system disorders6/5310/512/502/27
NauseaGastrointestinal disorders7/538/516/504/27
Diabetes mellitus inadequate controlMetabolism and nutrition disorders8/532/516/504/27
Back painMusculoskeletal and connective tissue disorders1/535/512/504/27
ArthralgiaMusculoskeletal and connective tissue disorders4/537/514/501/27
Urinary tract infectionInfections and infestations0/535/516/503/27
DiarrhoeaGastrointestinal disorders2/536/512/500/27
Abdominal pain upperGastrointestinal disorders6/534/513/503/27
HypertensionVascular disorders6/532/511/503/27
ConstipationGastrointestinal disorders3/534/515/503/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Seladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlaceboTotal
Mean53.3 ± 12.4856.6 ± 11.7453.7 ± 11.1853.9 ± 10.2754.4 ± 11.60
Sex: Female, Male
Sex: Female, Male(Participants)Seladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlaceboTotal
Female36353318122
Male171617959
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Seladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlaceboTotal
White50474927173
Black or African American11002
Asian11103
American Indian or Alaska native11002
Multiple01001
Region of Enrollment
Region of Enrollment(participants)Seladelpar 10 mgSeladelpar 20 mgSeladelpar 50 mgPlaceboTotal
United States53515027181
08

Study locations

14 sites
  • CymaBay Research Site
    Glendale, Arizona 85306, United States
  • CymaBay Research Site
    Tucson, Arizona 85712, United States
  • CymaBay Research Site
    Los Angeles, California 90057, United States
  • CymaBay Research Site
    Boca Raton, Florida 33434, United States
  • CymaBay Research Site
    Lakewood Ranch, Florida 34211, United States
  • CymaBay Research Site
    Flowood, Mississippi 39232, United States
  • CymaBay Research Site
    Clarksville, Tennessee 37040, United States
  • CymaBay Research Site
    Germantown, Tennessee 38138, United States
  • CymaBay Research Site
    Hermitage, Tennessee 37076, United States
  • CymaBay Research Site
    Knoxville, Tennessee 37909, United States
  • CymaBay Research Site
    Chandler, Texas 85224, United States
  • CymaBay Research Site
    Dallas, Texas 75246, United States
  • CymaBay Research Site
    Live Oak, Texas 78233, United States
  • CymaBay Research Site
    Rollingwood, Texas 78746, United States
09

References and documents

Publications

  • Beyer C, Hutton C, Andersson A, Imajo K, Nakajima A, Kiker D, Banerjee R, Dennis A. Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort. PLoS One. 2021 Apr 1;16(4):e0249491. doi: 10.1371/journal.pone.0249491. eCollection 2021. PubMed 33793651 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in May 2019, 12 months.

Results were first posted in Jul 2022, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2018
First posted
Jun 11, 2018
StartActual
Apr 30, 2018
Primary completionActual
May 8, 2019
CompletionActual
Aug 10, 2020
Results first posted
Jul 5, 2022
Last update
Sep 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03551522
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Apr 30, 2018
Primary completion
May 8, 2019
Completion
Aug 10, 2020
Results posted
Jul 5, 2022
Last update
Sep 15, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seladelpar

Start the discussion